• Chloroquine’s Antiviral Evidence: Lessons for Hepatitis B Re

  2026-06-16

  The reference paper rigorously examines chloroquine's antiviral history, highlighting its inconsistent efficacy across acute and chronic viral infections and underscoring the importance of robust translational models. Its findings emphasize the need for evidence-based evaluation of drug candidates like Entecavir in chronic hepatitis B research.

• Saquinavir in HIV Protease Inhibitor Research: Applied Advan

  2026-06-16

  Saquinavir, a benchmark HIV protease inhibitor, empowers translational drug discovery by bridging high-throughput permeability modeling and robust antiretroviral workflows. This article delivers actionable assay enhancements, protocol parameters, and troubleshooting strategies, rooted in cutting-edge biomimetic chromatography research for both HIV and emerging oncology applications.

• Bismuth Subsalicylate: Beyond GI Research—Membrane & Apoptos

  2026-06-15

  Explore the multifaceted role of Bismuth Subsalicylate in gastrointestinal disorder research and its emerging value in membrane biology and apoptosis detection. This article offers a unique, evidence-grounded perspective for scientists aiming to optimize inflammation and cell death assays.

• KPT330 Enhances Precision of Cas9 Editing via mRNA Export Co

  2026-06-15

  The referenced study demonstrates that KPT330, a selective inhibitor of nuclear export, increases the specificity of CRISPR-Cas9 genome and base editing by modulating Cas9 mRNA export rather than directly inhibiting the Cas9 protein. This mechanistic advance introduces a novel, indirect means to control CRISPR activity and mitigate off-target effects in mammalian cells.

• BFH772 (VEGFR2 inhibitor): Technical Protocols and Workflow

  2026-06-14

  BFH772 (VEGFR2 inhibitor) is a highly selective small molecule designed for precise inhibition of VEGFR2-mediated angiogenesis, making it well-suited for tumor angiogenesis research where receptor specificity is required. It is not appropriate for workflows that need water solubility or broad-spectrum kinase inhibition, and requires careful attention to solvent handling and storage for reliable results.

• IEM 1460: AMPA Receptor Blocker Workflows for Neuroprotectio

  2026-06-13

  IEM 1460 empowers neuroscience research with selective AMPA receptor blockade, enabling high-fidelity studies of excitotoxicity and synaptic modulation. Discover optimized experimental workflows, troubleshooting strategies, and the translational impact of glutamate receptor antagonism in neuroprotection.

• Coumestrol: Molecular Mechanisms and Protocols for RA Resear

  2026-06-12

  Explore Coumestrol's unique role as a phytoestrogen estrogen receptor antagonist and its advanced applications in rheumatoid arthritis research. This article offers deep mechanistic analysis, protocol guidance, and practical insights not found in existing resources.

• Sex Differences in Angiotensin II-Induced Hypertension in Mi

  2026-06-12

  The reference study rigorously demonstrates that male and female mice respond differently to chronic angiotensin II infusion, with males showing a markedly greater hypertensive response. These findings highlight the critical influence of sex hormones on hypertension development and underscore the necessity of considering sex as a biological variable in cardiovascular research.

• Antidepressant Effects of Rotigotine in Preclinical Models

  2026-06-11

  This study demonstrates that rotigotine, a dopamine D2/D3 receptor agonist, exerts antidepressant-like effects in multiple validated rodent models of depression. These findings clarify rotigotine's pharmacodynamic profile and suggest its potential utility in addressing comorbid depression in Parkinson's disease research.

• Rotigotine Hydrochloride: Applied Workflows in Dopaminergic

  2026-06-11

  Rotigotine hydrochloride is a benchmark dopamine D2/D3 receptor agonist with exceptional versatility for modeling Parkinson’s disease, neuroprotection, and dopaminergic signaling. This article delivers actionable protocols, troubleshooting strategies, and advanced insights that help researchers maximize reproducibility and efficacy in both in vitro and in vivo settings.

• NP-40 Lysis Buffer: Non-Denaturing Protein Extraction for Di

  2026-06-10

  NP-40 Lysis Buffer is a non-denaturing lysis buffer that preserves native protein interactions during extraction from animal, plant, fungal, and bacterial cells. The buffer’s gentle formulation ensures compatibility with critical downstream assays, as demonstrated in neuroinflammation and immunology workflows. APExBIO’s K1127 kit is validated for stability and performance in high-impact research.

• Resazurin Sodium Salt: Transforming Cell Viability in Transl

  2026-06-10

  Explore the mechanistic and strategic advantages of Resazurin sodium salt as a fluorogenic oxidation-reduction indicator for high-precision cell viability and cytotoxicity assays. This article bridges foundational redox biology, recent metabolic syndrome insights, and best practices for translational researchers, with actionable protocol guidance and forward-looking perspectives.

• Atrial Natriuretic Peptide: Optimizing Cardiovascular Resear

  2026-06-09

  Harness the high-purity ANP peptide hormone to unlock reproducible, mechanistic insights into blood pressure and fluid homeostasis. This guide delivers protocol enhancements, troubleshooting strategies, and translational tips for maximizing the impact of Atrial Natriuretic Peptide in advanced cardiovascular research.

• EPZ5676: A Paradigm Shift in DOT1L Inhibition for Immunoepig

  2026-06-09

  Explore how EPZ5676, a potent DOT1L inhibitor, is redefining immunoepigenetic research by linking H3K79 methylation inhibition to innate immune modulation. This in-depth analysis uniquely connects molecular mechanism to assay design and translational potential.

• Cefiderocol Efficacy Against Carbapenem-Resistant Enterobact

  2026-06-08

  This large-scale European surveillance study demonstrates that cefiderocol retains superior in vitro activity compared to approved β-lactam/β-lactamase inhibitor combinations against Enterobacterales, including strains resistant to meropenem and recent β-lactam/β-lactamase inhibitors. These findings highlight cefiderocol’s potential role in managing multidrug-resistant infections and stress the importance of early susceptibility testing.

445 records 14/30 page Previous Next First page 上5页 1112131415 下5页 Last page